Terence W Friedlander

Summary

Affiliation: University of California
Country: USA

Publications

  1. doi request reprint Looking back, to the future of circulating tumor cells
    Terence W Friedlander
    Division of Hematology and Medical Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, United States Electronic address
    Pharmacol Ther 142:271-80. 2014
  2. doi request reprint A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer
    Terence W Friedlander
    Genitourinary Medical Oncology Program, Biostatistics and Computational Biology Core, Helen Diller Family Comprehensive Cancer Center, Department of Bioengineering and Therapeutic Sciences, Box 1711, 1600 Divisadaro Street, University of California, San Francisco, San Francisco, CA 94115 1711, USA
    Oncol Rep 27:3-9. 2012
  3. doi request reprint Targeting the androgen receptor
    Terence W Friedlander
    Division of Genitourinary Medical Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA
    Urol Clin North Am 39:453-64. 2012
  4. doi request reprint Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study
    Terence W Friedlander
    Urologic Oncology Program, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143, USA
    Urol Oncol 30:408-14. 2012
  5. doi request reprint Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer
    Terence W Friedlander
    Division of Genitourinary Medical Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA
    Int J Cancer 134:2284-93. 2014
  6. pmc Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer
    Xiao X Wei
    University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California
    Cancer Immunol Res 4:948-958. 2016
  7. doi request reprint Common structural and epigenetic changes in the genome of castration-resistant prostate cancer
    Terence W Friedlander
    Division on Genitourinary Medical Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California 94143, USA
    Cancer Res 72:616-25. 2012
  8. doi request reprint An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer
    Gayatri Premasekharan
    Department of Urology, University of California, San Francisco UCSF, San Francisco, CA, USA
    Cancer Lett 380:144-52. 2016
  9. ncbi request reprint Updated results of a phase I/II trial of intravesical CG0070 in patients with superficial bladder cancer after BCG failure
    Terence W Friedlander
    University of California, San Francisco, San Francisco, CA Cold Genesys, Irvine, CA Jennerex, Inc, San Francisco, CA BCG Oncology, Phoenix, AZ Department of Urology, Columbia University College of Physicians and Surgeons, New York, NY Mary Crowley Cancer Research Center, Dallas, TX Cancer Centers of the Carolinas, Greenville, SC
    J Clin Oncol 30:271. 2012
  10. pmc Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens
    Won Kim
    Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California
    Clin Cancer Res 20:6269-76. 2014

Collaborators

Detail Information

Publications11

  1. doi request reprint Looking back, to the future of circulating tumor cells
    Terence W Friedlander
    Division of Hematology and Medical Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, United States Electronic address
    Pharmacol Ther 142:271-80. 2014
    ....
  2. doi request reprint A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer
    Terence W Friedlander
    Genitourinary Medical Oncology Program, Biostatistics and Computational Biology Core, Helen Diller Family Comprehensive Cancer Center, Department of Bioengineering and Therapeutic Sciences, Box 1711, 1600 Divisadaro Street, University of California, San Francisco, San Francisco, CA 94115 1711, USA
    Oncol Rep 27:3-9. 2012
    ..NDGA therapy lengthens median PSADT but does not induce significant PSA declines. Further study may require a placebo-control to determine if changes in PSADT are drug related...
  3. doi request reprint Targeting the androgen receptor
    Terence W Friedlander
    Division of Genitourinary Medical Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA
    Urol Clin North Am 39:453-64. 2012
    ....
  4. doi request reprint Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study
    Terence W Friedlander
    Urologic Oncology Program, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143, USA
    Urol Oncol 30:408-14. 2012
    ..In this study, the efficacy of depot octreotide acetate was prospectively evaluated in patients with CRPC...
  5. doi request reprint Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer
    Terence W Friedlander
    Division of Genitourinary Medical Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA
    Int J Cancer 134:2284-93. 2014
    ..Correlation with clinical data in future studies may yield further insight into the functional significance of these findings. ..
  6. pmc Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer
    Xiao X Wei
    University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California
    Cancer Immunol Res 4:948-958. 2016
    ..These results suggest that systemic GM-CSF can modulate T-cell infiltration in the tumor microenvironment. Cancer Immunol Res; 4(11); 948-58. ©2016 AACR...
  7. doi request reprint Common structural and epigenetic changes in the genome of castration-resistant prostate cancer
    Terence W Friedlander
    Division on Genitourinary Medical Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California 94143, USA
    Cancer Res 72:616-25. 2012
    ..Genes identified in this integrated genomic study point to new drug targets in CRPC, an incurable disease state which remains the chief therapeutic challenge...
  8. doi request reprint An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer
    Gayatri Premasekharan
    Department of Urology, University of California, San Francisco UCSF, San Francisco, CA, USA
    Cancer Lett 380:144-52. 2016
    ..CAM + FACS iCTC enrichment enables multiple downstream genomic characterizations across different tumor types. ..
  9. ncbi request reprint Updated results of a phase I/II trial of intravesical CG0070 in patients with superficial bladder cancer after BCG failure
    Terence W Friedlander
    University of California, San Francisco, San Francisco, CA Cold Genesys, Irvine, CA Jennerex, Inc, San Francisco, CA BCG Oncology, Phoenix, AZ Department of Urology, Columbia University College of Physicians and Surgeons, New York, NY Mary Crowley Cancer Research Center, Dallas, TX Cancer Centers of the Carolinas, Greenville, SC
    J Clin Oncol 30:271. 2012
    ..Updated results from a phase I/II study of CG0070 in patients with recurrent superficial bladder cancer (T1, Ta, Tcis) after BCG treatment are presented here...
  10. pmc Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens
    Won Kim
    Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California
    Clin Cancer Res 20:6269-76. 2014
    ..The purpose of this study was to determine the clinical utility of abiraterone and its impact on circulating androgens following ketoconazole...
  11. ncbi request reprint Novel hormonal approaches in prostate cancer
    Terence W Friedlander
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero Street, San Francisco, CA 94115, USA
    Curr Oncol Rep 11:227-34. 2009
    ....